INCREASED COMPLIANCE WITH TUMOR TREATING FIELDS IS PROGNOSTIC FOR IMPROVED SURVIVAL IN THE TREATMENT OF GLIOBLASTOMA: A SUBGROUP ANALYSIS OF THE EF-14 PHASE III TRIAL

被引：0
|
作者：
Ram, Z. [1 ]
机构：
[1] Tel Aviv Med Ctr & Sch Med, Tel Aviv, Israel
来源：
NEURO-ONCOLOGY | 2018年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P01.033
引用
收藏
页码：235 / 236
页数：2
相关论文
共 50 条
  • [1] Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial
    S. A. Toms
    C. Y. Kim
    G. Nicholas
    Z. Ram
    Journal of Neuro-Oncology, 2019, 141 : 467 - 473
  • [2] Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial
    Toms, S. A.
    Kim, C. Y.
    Nicholas, G.
    Ram, Z.
    JOURNAL OF NEURO-ONCOLOGY, 2019, 141 (02) : 467 - 473
  • [3] Tumor Treating Fields alters progression patterns in glioblastoma: An imaging analysis of the EF-14 Phase III trial
    Jeyapalan, Suriya
    Toms, Steven A.
    Hottinger, Andreas
    Kleinberg, Lawrence
    Pollom, Erqi
    Soltys, Scott G.
    Glas, Martin
    CANCER RESEARCH, 2019, 79 (13)
  • [4] COMPLIANCE AND TREATMENT DURATION PREDICT SURVIVAL IN A PHASE 3 EF-14 TRIAL OF TUMOR TREATING FIELDS WITH TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
    Ram, Zvi
    Kim, Chae-Yong
    Nicholas, Garth A.
    Toms, Steven
    NEURO-ONCOLOGY, 2017, 19 : 6 - 7
  • [5] Analysis of the EF-14 phase Ill trial reveals that tumor treating fields alter progression patterns in glioblastoma.
    Jeyapalan, Suriya A.
    Toms, Steven A.
    Hottinger, Andreas Felix
    Kleinberg, Lawrence
    Pollom, Erqi
    Soltys, Scott G.
    Glas, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] Analysis of the EF-14 Phase 3 Trial Reveals That Tumor-Treating Fields Alter Progression Patterns in Glioblastoma
    Jeyapalan, S.
    Toms, S. A.
    Hottinger, A.
    Kleinberg, L. R.
    Pollom, E.
    Soltys, S. G.
    Glas, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E100 - E101
  • [7] Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients with Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial
    Ram, Zvi
    Kim, Chae-Yong
    Hottinger, Andreas F.
    Idbaih, Ahmed
    Nicholas, Garth
    Zhu, Jay-Jiguang
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [8] THE COST EFFECTIVENESS OF TUMOR TREATING FIELDS TREATMENT FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA BASED ON THE EF-14 TRIAL
    Guzauskas, Gregory
    Wang, Bruce C. M.
    Pollom, Erqi
    Stieber, Volker W.
    Garrison, Lou
    NEURO-ONCOLOGY, 2018, 20 : 116 - 116
  • [9] Increasing Tumor Treating Fields dose at the tumor bed improves survival: Setting a framework for TTFields dosimetry based on analysis of the EF-14 Phase III trial in newly diagnosed glioblastoma
    Ballo, Matthew T.
    Urman, Noa
    Bomzon, Ze'ev
    Lavy-Shahaf, Gitit
    Toms, Steven
    CANCER RESEARCH, 2019, 79 (13)
  • [10] Perspective on the EF-14 trial and its implications for the role of tumor-treating fields in the management of glioblastoma
    Mohan, Suyash
    Chawla, Sanjeev
    Skolnik, Aaron
    Poptani, Harish
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S272 - S275
12345